Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework

Last updated: November 3, 2024
Sponsor: University of Vermont
Overall Status: Completed

Phase

N/A

Condition

Tardive Dyskinesia

Dystonias

Neurologic Disorders

Treatment

Telemedicine Consult

In-person Consult

Clinical Study ID

NCT06060444
STUDY00001579
  • Ages > 18
  • All Genders

Study Summary

In this pilot study, the investigators will evaluate care delivery via telemedicine to individuals with drug-induced movement disorders (DIMDs). DIMDs can be disabling, and prevention is important; but these disorders are often under-reported, under-recognized and poorly managed. Interprofessional telemedicine for movement disorders is feasible and may provide similar care as in-person visits; however, the majority of studies to date have shown benefit in Parkinson's disease and further validation in other movement disorders is necessary.

In this randomized controlled trial the aim is to study the acceptability, feasibility, and patient and clinician outcomes when a neurological consultation is provided for patients with DIMDs either in-person or through telemedicine. The investigators will apply the evaluation framework RE-AIM (Reach and Effectiveness, Adoption, Implementation, and Maintenance) to comprehensively assess the factors that may impact study success and program implementation. Mixed methods will be implemented to gather outcome data from mental health clinicians that refer patients and the patient participants.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years or older

  • Willing and able to provide consent

  • Willing to have their Mental Health Clinician (MHC) share sensitive clinicalinformation with the Neurology team

  • Able to travel to Neurology clinic

  • Have connectivity to Zoom using wi-fi or cellular data, either at home or acomfortable and private setting (such as MHC office)

Exclusion

Exclusion Criteria:

  • Currently hospitalized

  • Neurologist determines patient requires care outside of the scope of the study

Study Design

Total Participants: 28
Treatment Group(s): 2
Primary Treatment: Telemedicine Consult
Phase:
Study Start date:
April 26, 2022
Estimated Completion Date:
October 31, 2024

Connect with a study center

  • University of Vermont Medical Center

    Burlington, Vermont 05401
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.